Bosutinib medication instructions

Bosutinib (Bosutinib, trade name: Bosulif), as a highly effective tyrosine kinase inhibitor, is produced by Pfizer and is mainly used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in the chronic phase, accelerated phase or blast phase. The drug achieves therapeutic purposes by specifically inhibiting the activity of BCR-ABL kinase and inhibiting Src family kinases. This article is the drug insert for bosutinib.

1. Usage

1. Use medication strictly as directed. Do not stop using it without your doctor's advice.

2.xa0整个吞下药片，不要压碎、咀嚼或弄碎它。 Medication in crushed or broken pills can be dangerous if it comes into contact with your skin. If this happens, wash skin with soap and water.

3. If you miss a dose, take it as soon as possible, but if it is more than 12 hours late, skip it.

4. Avoid using products containing grapefruit. Grapefruit may interact with bosutinib and cause unwanted side effects. Also, tell your doctor about all the medicines you take.

2. Dosage

1. Adults with newly diagnosed chronic phasePh+ CML patients: 400 mg, taken orally once daily with food.

2. Adult patients with chronic, accelerated phase or blast phase Ph+ CML who are resistant or intolerant to previous treatments: 500 mg orally, once daily, with food.

3. Newly diagnosed pediatric chronic phasePh+ CML: 300mg/m², taken orally once a day with food.

4. Chronic phase with resistance or intolerance to previous treatmentsPh+ CML pediatric patients: 400 mg/m^2, taken orally once daily with food.

5. In clinical studies in adult patients with Ph+ CML, dose escalation from 100 mg once daily to a maximum of 600 mg once daily was allowed for patients who did not achieve or maintain a hematological, cytogenetic, or molecular response and who had no grade 3 or higher adverse reactions at the recommended starting dose.

6. For pediatric patients who have not achieved adequate remission after 3 months, consideration may be given to increasing the dose to 50 mg for patients with BSA <1.1 m²50 mg, BSA≥1.1 For patients with m² dose increase100 mg to a maximum daily dose of 600 mg.

7. Adjust dosage based on toxicity and organ damage.

3. Precautions

1. Gastrointestinal toxicity

The use of bosutinib may cause gastrointestinal discomfort, such as diarrhea, nausea, and vomiting. Patients should be regularly monitored for symptoms and treated if necessary. The doctor may adjust the dose or discontinue the medication based on the patient's specific condition.

2. Myelosuppression

Bosutinib may affect patients' bone marrow function, leading to neutropenia, anemia, and thrombocytopenia. Patients should undergo regular complete blood counts and receive symptomatic treatment when necessary.

3. Hepatotoxicity

During the early stages of treatment, patients should have liver enzyme levels checked at least monthly to monitor liver function. If liver function abnormalities occur, your doctor may adjust the dose or discontinue the drug.

4. Fluid retention

Patients should be regularly monitored for fluid retention and treated if necessary. The doctor may adjust the dose or discontinue the medication based on the patient's specific condition.

5. Nephrotoxicity

During medication, patients should undergo regular renal function tests.

6. Embryo-fetal toxicity

Bosutinib may have adverse effects on the embryo and fetus. Therefore, women of childbearing potential should avoid becoming pregnant while taking this medication.

4. Adverse reactions

Bosutinib may cause a variety of adverse reactions, including but not limited to diarrhea, nausea, vomiting, abdominal pain, neutropenia, anemia, thrombocytopenia, etc. In addition, some rare adverse reactions may occur, such as febrile neutropenia, pericardial effusion, pericarditis, tinnitus, etc. If serious adverse reactions occur, patients should seek medical treatment immediately.

5. Storage conditions

Bosutinib should be stored in a dark, dry, sealed, and cool place. Please ensure that the medicine is used within the expiry date.

6. Price

The price of bosutinib varies by manufacturer, version and region. For example, there may be price differences between the Indian Mylan version, the Turkish Pfizer version, and the European Pfizer version.

Please note that the above information is for reference only. The specific usage, dosage, precautions and adverse reactions should be determined based on the patient's specific situation and the doctor's advice. Before using bosutinib, patients should fully understand its relevant information and use it under the guidance of a doctor.